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Objectives: Advances in surgical techniques and chemotherapeutic options have expanded indications
for surgery in patients with metastatic colorectal cancer. This study aimed to examine how hepatopan-
creatobiliary (HPB) surgeons approach the management of patients with hepatic colorectal cancer
metastases (HCCM).
Methods: A web-based survey utilizing 10 clinical scenarios was distributed by e-mail to 37 HPB
surgeons in Ontario, Canada. The study region has a population of approximately 13 million people
and a universal, single-payer health care system. Descriptive analyses were used to tabulate
results.
Results: Twenty-two (59%) surgeons responded to the survey. The majority (19/22, 86%) of
respondents favoured neoadjuvant chemotherapy for patients with multiple synchronous and
unilobar metastases; only nine of 22 (41%) respondents favoured neoadjuvant chemotherapy for
patients with a single synchronous metastasis. In the setting of residual resectable disease following
downstaging chemotherapy, 77% (17/22) of surgeons advocated hepatic resection with either radiof-
requency ablation (RFA) or wedge resection of the ‘ghost’ lesions. Over 80% of surgeons would
perform a liver and pulmonary resection in a patient with hepatic and multiple unilobar lung
metastases. None would offer liver resection to patients with multiple retroperitoneal node involvement,
although 55% (12/22) would do so if a single retroperitoneal node was involved. Preoperative portal
vein embolization was favoured over RFA in patients with a small metastasis and inadequate functional
hepatic volume.
Conclusions: Notable heterogeneity was observed among Ontario's HPB surgeons in approaches to
HCCM.
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Introduction
Colorectal cancer is the third leading cause of cancer-related mor-
tality in men and women worldwide. Every year, 120 000 new
cases of colorectal cancer and 600 000 deaths are reported.1
Approximately one quarter of colorectal cancer patients present
with metastases at diagnosis and an additional 30–40% will
develop hepatic metastases during the course of the disease.2 Sur-
gical resection is the only definitive curative modality for hepatic
colorectal cancer metastases (HCCM).3–6 Complete resection of
metastatic disease results in 5-year survival rates of 36–58%.4,7–12
Over the last decade, advances in surgical techniques and
chemotherapeutic and biologic agents have considerably
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broadened surgical indications for patients with metastatic col-
orectal cancer. With such rapid and substantive expansion of
resection criteria, there is potential for variation in surgical prac-
tice. Morris et al. found considerable variation in liver resection
rates across cancer networks and hospitals in England between
January 1998 and June 2004.12 Notably, significant variation per-
sisted across both hospitals and cancer networks, despite adjust-
ments for case mix; in a number of networks and hospitals
identified as outliers, patients were significantly more likely to
undergo resection for hepatic metastases. It is unclear whether this
heterogeneity is attributable to variation in referral practices, dif-
ferences in subsequent access to hepatopancreatobiliary (HPB)
specialists or to surgeons’ varying thresholds for resectability. This
paper reports the findings of a web-based survey conducted to
explore whether the latter may influence approaches to both
‘simple’ and complex clinical cases of HCCM among HPB sur-
geons in Ontario, Canada.
Materials and methods
In April 2008, an online survey was distributed to 37 surgeons who
perform HPB surgical procedures in Ontario, Canada. The study
region has a population of approximately 13 million people and a
universal, single-payer health care system. Surgeons were identi-
fied via their membership in the Cancer Care Ontario HPB Com-
munity of Practice. Cancer Care Ontario, which is governed by the
Cancer Act of Ontario, is a provincial agency that directs and
oversees public health care expenditures for cancer services and
oncologic quality improvement initiatives. Study subjects were
contacted by e-mail and invited to participate in this anonymous
survey. They received two reminders by e-mail at 4 weeks and
2 weeks prior to the response deadline. Those who failed to meet
the deadline received an additional telephone call reminder.
This web-based survey comprised 10 items, each probing one
or two of the following management issues for patients with
HCCM: (i) the role of perioperative chemotherapy; (ii) the role of
downstaging chemotherapy and surgical approach thereafter; (iii)
the role of liver resection in the presence of extrahepatic disease,
and (iv) the use of radiofrequency ablation (RFA) as a preferred or
adjunctive component to surgery. Prior to distribution, the survey
was piloted by five individuals with content expertise in HPB
surgical oncology and survey methods. The clinical scenarios were
subsequently revised to eliminate ambiguity. Descriptive analyses
were used to tabulate results.
Results
Of the 37 surgeons who were e-mailed an invitation to participate,
22 (59%) responded to the survey. Nine respondents (40%) prac-
tised at centres that met Cancer Care Ontario’s HPB Surgical
Oncology Standards at the time (i.e. at least 50 HPB surgical
procedures were performed yearly and a minimum of 20 of these
operations were pancreatic resections). Over 95% of respondents
(n = 21) answered all questions.
‘Upfront’ surgery vs. neoadjuvant chemotherapy
Participants were presented with two scenarios featuring synchro-
nous disease. In the first case, a single metastasis is discovered
intraoperatively during resection of a primary colon cancer. The
HPB surgeon is consulted postoperatively for his or her opinion
regarding subsequent management. Respondents were slightly
more in favour of ‘upfront’ surgery followed by ‘pseudoadjuvant’
chemotherapy (chemotherapy delivered after liver resection) (13/
22, 59%), rather than neoadjuvant chemotherapy (9/22, 41%)
(Table 1a). In the second case, the patient presents with multiple
synchronous liver metastases limited to one lobe. Considerably
more respondents in this instance suggested neoadjuvant chemo-
therapy (19/22, 86%) and only three (14%) advocated upfront
surgery and subsequent chemotherapy (Table 1b).
In another scenario, a young patient presents with multiple
HCCM in the right lobe and a single metastasis in the left lateral
segment, 3 years after colon resection for stage III cancer.
She has undergone appropriate adjuvant chemotherapy in the
interim. Eleven (50%) of the 22 respondents favoured upfront
surgery and nine (41%) favoured neoadjuvant chemotherapy
(Table 2). Two (9%) participants chose palliative chemotherapy
alone.
When the same pattern of liver disease was presented synchro-
nously with the primary colon cancer, the majority of surgeons
opted for immediate neoadjuvant chemotherapy and restaging
(n = 18, 82%); opinion among the remaining respondents was
divided between upfront surgery (n = 2, 9%) and palliative che-
motherapy (n = 2, 9%) (Table 3). There was no support for an
immediate staged resection.
Participants were asked about their approach to a patient with
an asymptomatic rectal cancer (T3N1, 9 cm from the anal verge)
Table 1 Responses to items on treatment proposals for two patients
with right-sided colon cancer and HCCM (n = 22 respondents)
(a) The patient is aged 67 years and has a right-sided colon
cancer (T3N1) resected at an outside hospital 2 weeks ago.
HCCM is noted intraoperatively. CT of the abdomen
demonstrates a single lesion in the middle of the right lobe
Answer option n (%)
Neoadjuvant chemotherapy 9 (40.9%)
Upfront surgery
• Right hepatic lobectomy followed by
pseudoadjuvant chemotherapy
13 (59.1%)
(b) The patient is aged 67 years and has a right-sided colon
cancer (T3N1) resected at an outside hospital 2 weeks ago.
HCCM is noted intraoperatively. CT of the abdomen
demonstrates six lesions in the right lobe
Answer option n (%)
Neoadjuvant chemotherapy 19 (86.4%)
Upfront surgery
• Right hepatic lobectomy followed by
adjuvant chemotherapy
3 (13.6%)
HCCM, hepatic colorectal cancer metastasis; CT, computed
tomography.
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in the setting of liver metastases. Sixteen (73%) respondents
chose neoadjuvant chemoradiotherapy as the initial treatment
for the rectal cancer, followed by surgery, whereas four (18%)
recommended a low anterior resection without neoadjuvant
chemoradiotherapy. One surgeon chose chemotherapy alone,
suggesting a palliative approach to this patient. No participant
chose simultaneous low anterior resection and right hepatic
lobectomy as initial therapy.
Downstaging chemotherapy
Participants were presented with a scenario involving a 62-year-
old man, 2 years after resection of stage II colon cancer. This
patient has liver metastases that are considered unresectable, with
one lesion in each of segments II, III, IVa, IVb and VII. After
8 months of chemotherapy, the left-sided lesions are smaller and
the segment VII lesion is no longer visible (i.e. it has become a
‘ghost’ lesion). Two (9%) surgeons deemed this pattern of disease
incurable and recommended continued chemotherapy. The
remaining surgeons chose a more aggressive approach. Eighteen
(82%) surgeons chose treatment regimens specifically designed to
achieve loco-regional control of the ghost lesion with a left hepatic
lobectomy and either a wedge resection (n = 17) or RFA (n = 1).
One respondent considered the ghost lesion to be biologically
inactive and selected left hepatic lobectomy alone, and another
preferred to stop chemotherapy and assess for interval disease
progression before pursuing a left hepatic lobectomy if the ghost
lesion failed to reappear.
An additional scenario probed the surgeons’ willingness to con-
sider high-risk operations involving hepatic vein reconstruction.
In this instance, a 58-year-old patient presents with two
metastases straddling all three hepatic veins, 3 years after resection
of a stage II cecal adenocarcinoma. The scenario specifies that a
right trisegmentectomy and re-implantation of the left hepatic
vein will be required to achieve an R0 resection. There was signifi-
cant heterogeneity among the 21 participants who responded to
this item. Three (14%) surgeons chose palliative chemotherapy,
whereas six (29%) suggested that such a patient should be referred
to another centre. Eight (38%) respondents suggested initial
downstaging chemotherapy and four (19%) favoured upfront
surgery. In this instance, upfront surgery was defined as a right
trisegmentectomy and re-implantation of the left hepatic vein. Of
note, the four surgeons who chose upfront surgery practised at a
transplant centre.
Extrahepatic disease
When challenged by patients with both lung and liver metastases,
the majority of the 22 respondents offered surgery in the setting of
unilobar lung involvement, and 10 (45%) offered surgery to those
patients with bilobar lung disease. Fewer surgeons were in favour
of combining hepatic resection with portal lymphadenectomy; six
(27%) suggested a hilar lymphadenectomy and six (27%) recom-
mended a ‘node picking’ procedure (Table 4). No respondent
offered liver surgery when metastatic disease was present in mul-
tiple retroperitoneal nodes, although 12 (55%) favoured surgery if
only a single retroperitoneal node was involved. Seventeen (77%)
respondents suggested liver resection in conjunction with the
removal of a single persistent node in the mesentery of a previ-
ously resected colon cancer, but only three (14%) suggested this
surgery in the setting of multiple mesenteric nodal metastases.
Radiofrequency ablation vs. surgery
Finally, the surgeons were presented with a patient with a single
2-cm metachronous metastasis in the middle of the right lobe of
the liver. In this patient, the left lobe is prohibitively small, con-
stituting 20% of total liver volume. Five (23%) of the 22 surgeons
Table 2 Responses to an item on treatment proposals for a 55-year-
old patient with eight metastases in the right lobe and a 2.5-cm
metastasis in segment III, 3 years after resection of a primary stage
III colon cancer and adjuvant chemotherapy (n = 22 respondents)
Answer option n (%)
Referral to medical oncology for neoadjuvant
chemotherapy followed by restaging and possible
surgery
9 (40.9%)
Upfront surgery
• Right portal vein embolization followed by right
hepatic lobectomy and left lateral segmentectomy
3 (13.6%)
• Right hepatic lobectomy and radiofrequency
ablation of left lateral segment metastasis
2 (9.1%)
• Staged resection:
• Left lateral wedge resection of segment III lesion
and ligation of the right portal vein followed by right
hepatic lobectomy if adequate regeneration
4 (18.2%)
• Right hepatic lobectomy followed by left lateral
segmentectomy if adequate regeneration of left lobe
2 (9.1%)
Referral to medical oncology for palliative chemotherapy 2 (9.1%)
Table 3 Responses to an item on treatment proposals for a 55-year-
old patient with a primary stage III colon cancer and eight
metastases in the right lobe and a 2.5-cm metastasis in segment III
(n = 22 respondents)
Answer option n (%)
Referral to medical oncology for neoadjuvant
chemotherapy followed by restaging and possible
surgery
18 (81.8%)
Upfront surgery
• Right portal vein embolization followed by right
hepatic lobectomy and left lateral segmentectomy
1 (4.5%)
• Right hepatic lobectomy and radiofrequency
ablation of left lateral segment metastasis
1 (4.5%)
• Left lateral wedge resection of segment III lesion,
ligation of the right portal vein followed by right
hepatic lobectomy if adequate regeneration
0
• Staged resection 0
Referral to medical oncology for palliative chemotherapy 2 (9.1%)
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suggested RFA of the liver lesion in lieu of surgical management
and the remaining 17 (77%) favoured portal vein embolization
(PVE) followed by surgery.
Discussion
The aim of this survey was to assess the approaches of Ontario
HPB surgeons in hypothetical scenarios concerning issues
currently under debate in HPB surgery, in an era prior to the
development of provincial consensus guidelines (April 2008).
Variations in practice were apparent in responses to many of the
clinical scenarios presented in the 10-item survey.
The only contemporary trial to address the question of perio-
perative chemotherapy for HCCM found a statistical trend
towards increased survival with the use of neoadjuvant (‘sand-
wich’) chemotherapy; however, patients in the comparator arm
received surgical resection alone without any chemotherapy.13
Respondents were clearly divided between the administration of
pseudoadjuvant and neoadjuvant chemotherapy (Table 1) for the
patient with a single synchronous HCCM in the right lobe. To
date, there is insufficient evidence in support of one approach vs.
the other and until data from randomized trials become available,
varied practice patterns are likely to continue. Currently, multi-
centre trials are underway to assess the benefits of preoperative vs.
postoperative chemotherapy in this setting.14
Liver surgery for patients with HCCM and extrahepatic
metastases remains controversial.3 Portal lymph node involve-
ment has been investigated by a number of studies that have
reported few or no survivors at 5 years among HCCM patients
who underwent therapeutic portal lymphadenectomy for
involved nodes, especially distal field or celiac nodes.15–19 A signifi-
cant proportion of surgeons surveyed in the present study said
they would consider resection of extrahepatic disease including
portal (6/22, 27%), retroperitoneal (12/22, 55%) and mesenteric
(3–17/22, 14–77%) lymph nodes, which suggests they have incor-
porated recent Level II evidence into their practice.20 Based on a
number of retrospective studies,21–23 complete resection of lung
and liver metastases is generally accepted as the standard of care;
these studies have demonstrated that the survival of patients who
undergo pulmonary and liver metastastectomy is comparable
with that of patients with isolated liver metastases. Not surpris-
ingly then, the majority of respondents to the present survey
(21/22, 95%) did not consider an isolated, single pulmonary col-
orectal cancer metastasis a contraindication to hepatectomy.
However, the number of surgeons in favour of hepatectomy fell
when the patient exhibited multiple metastatic lesions isolated to
a single pulmonary lobe. Because the literature published on this
topic is limited, the extent of pulmonary disease burden that
should be considered amenable to surgery is still debatable.
The utility of PVE for increasing the size of the future liver
remnant (FLR) prior to a major liver resection is well established.
The majority (17/22, 77%) of participants in the present survey
chose PVE for a patient requiring a right hepatic lobectomy with an
anticipated FLR of <20%. However, five (23%) surgeons chose
instead to achieve loco-regional control of the single right-sided
metastasis with an ablative technique rather than PVE and surgery.
To date, there is no Level I evidence to suggest that RFA is equivalent
to surgery in its likelihood of achieving a cure in HCCM.
This survey used an anonymous, online, electronic, multiple-
choice questionnaire and is subject to the shortcomings of such
instruments.24 Nonetheless, its findings demonstrate variation in
approaches to patients with HCCM, despite active efforts around
the time of the survey to regionalize HPB surgical oncology care in
Ontario. Although complete uniformity in surgical management
is unrealistic and unnecessary, further efforts in developing and
implementing surgical guidelines should lead to the provision of
more consistent care for these complex patients.
Conclusions
The present study demonstrates heterogeneity in the approach to
HCCM among Ontario HPB surgeons. Given the relatively low
volume and high acuity of HPB surgical oncology patients, it
seems feasible that greater consistency in care is possible for these
patients, assuming they have relatively equal access to specialized
centres. Recent efforts to resolve some of the more important
clinical questions in the specialty with prospective, randomized
trials should also reduce controversy and heterogeneity of care in
a specialty fraught by a paucity of Level I evidence.
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Table 4 Responses to the item: In which of the following scenarios
would you perform a hepatic resection in combination with resection
of extrahepatic disease at the same time or at a subsequent opera-
tion (assume a disease-free interval of >12 months from the primary
operation and an asymptomatic patient) (n = 22 respondents)
Answer option n (%)
Lung metastases
• Single lung metastasis 21 (95.5%)
• Multiple lung metastases involving a single lobe 18 (81.8%)
• Multiple lung metastases involving two lobes 10 (45.5%)
Portal lymph node metastases
• Node picking 6 (27.3%)
• Hilar lymphadenectomy 6 (27.3%)
Retroperitoneal metastases
• Solitary retroperitoneal lymph node 12 (54.5%)
• Multiple retroperitoneal lymph nodes 0
Mesenteric metastases
• Solitary metastasis within mesentery of resected
colonic primary
17 (77.3%)
• Multiple nodal metastases within mesentery of
resected colonic primary
3 (13.6%)
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